logo
Plus   Neg
Share
Email

Seelos To Use Aptar Pharma's Bidose Liquid System Device With SLS-002 Program

Seelos Therapeutics, Inc. (SEEL) has signed an agreement with AptarGroup, Inc. (ATR) for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System device for Seelos' intranasal ketamine product candidate, SLS-002, in the investigational development programs for the treatment of suicidality, depression, and Post-Traumatic Stress Disorder.

Aptar's patented BDS Liquid System has been approved by the FDA and European Medicines Agency for the delivery of other therapeutics.

Raj Mehra, Chairman and CEO of Seelos, said: "This partnership strengthens the collaboration between Seelos and Aptar, and further protects the SLS-002 franchise."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission said people should stop using Peloton Interactive's treadmills "Peloton Tread+" if small children or pets are around. The urgent warning comes less than a month after the exercise equipment maker itself released news of a child's death by a Peloton Tread+ and CPSC's announcement of an investigation into that incident. The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC.
Follow RTT